Whether HIV patients had hepatitis or not didn't change the link between losing visceral fat and improving liver enzymes.

62

Pro

0

Against

Evidence from Studies

Supporting (1)

62

Community contributions welcome

62

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV

Randomized Controlled Trial

Human

2017 Oct 23

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Source Study

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV

Score: 62

DOI: 10.1097/QAD.0000000000001614

Similar Assertions

For HIV patients with belly fat and high liver enzymes, losing visceral fat improved liver enzymes whether they had hepatitis or not.

62

0

96%

Whether HIV patients had hepatitis or not didn't change the link between losing visceral fat and improving liver enzyme levels.

62

0

85%

Whether people with HIV had hepatitis or not didn't change the relationship between losing belly fat and improving liver enzymes.

62

0

85%

For HIV patients with belly fat and high liver enzymes, taking a placebo even if they lost visceral fat didn't help lower their liver enzyme levels, unlike those taking the actual drug.

62

0

81%

Whether HIV patients had hepatitis or not didn't change the benefit of visceral fat loss on liver enzymes when taking tesamorelin.

62

0

80%